The economics of bladder cancer: Costs and considerations of caring for this disease

Medicine and Dentistry

• Health Care Cost 100%
• Bladder Cancer 58%
• Surveillance 33%
• Patient 33%
• Therapeutic Procedure 25%
• Diseases 16%
• Cisplatin 16%
• Combination Therapy 16%
• Diagnosis 16%
• Bladder Tumor 16%
• Non Muscle Invasive Bladder Cancer 16%
• Systematic Review 16%
• Neoplasm 8%
• Metastatic Carcinoma 8%
• Morbidity 8%
• Fulguration 8%
• Cystectomy 8%
• Transitional Cell Carcinoma 8%
• Recurrent Disease 8%
• Transurethral Resection 8%
• Gemcitabine 8%
• Vinblastine 8%
• Doxorubicin 8%
• Perioperative Period 8%
• Disease Severity 8%
• Methotrexate 8%
• Postoperative Care 8%
• Recurrence Risk 8%
• Cancer Therapy 8%
• Evaluation Study 8%

Nursing and Health Professions

• Bladder Cancer 58%
• Diseases 16%
• Perioperative 16%
• Diagnosis 16%
• Combination Therapy 16%
• Medical Subject Headings 16%
• Non Muscle Invasive Bladder Cancer 16%
• Electric Potential 16%
• Inpatient 16%
• Cisplatin 16%
• Bladder Tumor 16%
• Medline 8%
• Morbidity 8%
• Perioperative Period 8%
• Cost Effectiveness Analysis 8%
• Length of Stay 8%
• Recurrent Disease 8%
• Transitional Cell Carcinoma 8%
• Cystectomy 8%
• Metastasis 8%
• Neoplasm 8%
• Chemotherapy 8%
• Cost Control 8%
• Disease Severity 8%
• Postoperative Care 8%
• Recurrence Risk 8%
• Terminal Care 8%
• Cancer Therapy 8%
• Evaluation Study 8%
• Procedures 8%
• Synthesis 8%
• Cauterization 8%
• Doxil 8%
• Methotrexate 8%
• Transurethral Resection 8%
• Gemcitabine 8%
• Vinblastine 8%